PL3902548T3 - Inhibitor egfr z powodującą oporność na leczenie mutacją l718 i/lub l792 do stosowania w leczeniu nowotworu - Google Patents

Inhibitor egfr z powodującą oporność na leczenie mutacją l718 i/lub l792 do stosowania w leczeniu nowotworu

Info

Publication number
PL3902548T3
PL3902548T3 PL19839172.4T PL19839172T PL3902548T3 PL 3902548 T3 PL3902548 T3 PL 3902548T3 PL 19839172 T PL19839172 T PL 19839172T PL 3902548 T3 PL3902548 T3 PL 3902548T3
Authority
PL
Poland
Prior art keywords
treatment
cancer
egfr inhibitor
mutant
resistant egfr
Prior art date
Application number
PL19839172.4T
Other languages
English (en)
Inventor
Shinichi Hasako
Takao Uno
Original Assignee
Taiho Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=69174561&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3902548(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Taiho Pharmaceutical Co., Ltd. filed Critical Taiho Pharmaceutical Co., Ltd.
Publication of PL3902548T3 publication Critical patent/PL3902548T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PL19839172.4T 2018-12-28 2019-12-27 Inhibitor egfr z powodującą oporność na leczenie mutacją l718 i/lub l792 do stosowania w leczeniu nowotworu PL3902548T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018247131 2018-12-28
PCT/JP2019/051377 WO2020138400A1 (en) 2018-12-28 2019-12-27 L718 and/or l792 mutant treatment-resistant egfr inhibitor

Publications (1)

Publication Number Publication Date
PL3902548T3 true PL3902548T3 (pl) 2025-07-28

Family

ID=69174561

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19839172.4T PL3902548T3 (pl) 2018-12-28 2019-12-27 Inhibitor egfr z powodującą oporność na leczenie mutacją l718 i/lub l792 do stosowania w leczeniu nowotworu

Country Status (20)

Country Link
US (2) US20220072000A1 (pl)
EP (1) EP3902548B1 (pl)
JP (1) JP7303303B2 (pl)
KR (1) KR102930628B1 (pl)
CN (1) CN113423403B (pl)
AU (1) AU2019417691B2 (pl)
BR (1) BR112021012687A2 (pl)
DK (1) DK3902548T3 (pl)
ES (1) ES3033635T3 (pl)
FI (1) FI3902548T3 (pl)
HU (1) HUE071862T2 (pl)
IL (1) IL284330B2 (pl)
MX (1) MX2021007852A (pl)
PH (1) PH12021551545A1 (pl)
PL (1) PL3902548T3 (pl)
PT (1) PT3902548T (pl)
SG (1) SG11202106986VA (pl)
TW (1) TWI837266B (pl)
WO (1) WO2020138400A1 (pl)
ZA (1) ZA202104679B (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022007841A1 (zh) * 2020-07-09 2022-01-13 上海和誉生物医药科技有限公司 一种egfr抑制剂、其制备方法和在药学上的应用
US20230372346A1 (en) * 2020-09-08 2023-11-23 Cullinan Pearl Corp. Treatment regimens for exon-20 insertion mutant egfr cancers
CA3213079A1 (en) 2021-04-13 2022-10-20 Kristin Lynne ANDREWS Amino-substituted heterocycles for treating cancers with egfr mutations
WO2026095022A1 (ja) * 2024-11-01 2026-05-07 大鵬薬品工業株式会社 キノリン置換化合物の結晶

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016003247B1 (pt) * 2013-08-22 2022-05-10 Taiho Pharmaceutical Co., Ltd Composto substituído por quinolina, composição farmacêutica compreendendo o referido composto e seu uso
JP6468611B2 (ja) * 2014-05-13 2019-02-13 アリアド ファーマシューティカルズ, インコーポレイテッド キナーゼ阻害のためのヘテロアリール化合物
MX390435B (es) * 2016-10-31 2025-03-20 Taiho Pharmaceutical Co Ltd Inhibidor selectivo de receptor de factor de crecimiento epidermico mutante de insercion de exon 20.
AU2018325819B2 (en) * 2017-09-01 2024-02-01 Taiho Pharmaceutical Co., Ltd. Exon 18 and/or exon 21 mutant EGFR selective inhibitor

Also Published As

Publication number Publication date
KR102930628B1 (ko) 2026-02-25
WO2020138400A1 (en) 2020-07-02
TWI837266B (zh) 2024-04-01
SG11202106986VA (en) 2021-07-29
US20250144103A1 (en) 2025-05-08
IL284330A (en) 2021-08-31
US20220072000A1 (en) 2022-03-10
JP2022522573A (ja) 2022-04-20
ZA202104679B (en) 2023-12-20
KR20210110329A (ko) 2021-09-07
CN113423403A (zh) 2021-09-21
PH12021551545A1 (en) 2022-08-15
MX2021007852A (es) 2021-08-11
HUE071862T2 (hu) 2025-09-28
EP3902548A1 (en) 2021-11-03
CA3124750A1 (en) 2020-07-02
AU2019417691A1 (en) 2021-07-22
DK3902548T3 (da) 2025-07-07
BR112021012687A2 (pt) 2021-09-28
FI3902548T3 (fi) 2025-07-17
EP3902548B1 (en) 2025-05-28
IL284330B1 (en) 2025-11-01
PT3902548T (pt) 2025-06-27
TW202038965A (zh) 2020-11-01
ES3033635T3 (en) 2025-08-06
CN113423403B (zh) 2025-02-18
IL284330B2 (en) 2026-03-01
AU2019417691B2 (en) 2025-07-10
JP7303303B2 (ja) 2023-07-04

Similar Documents

Publication Publication Date Title
IL281999A (en) YAP/TAZ-TEAD interaction inhibitors and their use in cancer therapy
IL272948A (en) ENPP1 inhibitors and their use for cancer treatment
IL283149A (en) 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer
HUE069231T2 (hu) Aprocitentán magas vérnyomás és kapcsolódó betegségek kezelésében történõ alkalmazásra, kombinációban valzartánnal
IL279347A (en) Gremlin-1 antagonist for cancer prevention and treatment
IL283938A (en) Compounds and their use in the treatment of a1-antitrypsin deficiency
HUE071862T2 (hu) L718 és/vagy L792 mutáns, kezelésre rezisztens EGFR inhibitor rák kezelésében történõ alkalmazásra
IL281495A (en) Quinuclidine-3-one derivatives and their use in cancer treatment
IL272929A (en) Selective inhibitor for EGFR mutant exon 18 and/or exon 21
SI4340842T1 (sl) Sotorasib za uporabo pri zdravljenju raka
HUE055747T2 (hu) EGFR-gátló és MEK-gátló kombinációja NRAS-mutált rák kezelésében történõ alkalmazásra
GB201918404D0 (en) Compounds and their use for the treatment of aplha1-antitrypsin deficiency
IL287050A (en) Compounds for the treatment of oncovirus induced cancer and methods of use thereof
IL280262A (en) Compositions and methods for treating cancer
HUP1900281A1 (hu) Monoamin-oxidáz-B gátlók prosztata karcinóma megelõzésében vagy kezelésében történõ alkalmazásra
IL277112A (en) Compounds for inhibiting protein degradation and methods of use thereof in the treatment of cancer
AU2019902712A0 (en) Inhibitors and use thereof in cancer treatment
GB201908110D0 (en) Compositions and methods for use in the treatment of cancer-related fatigue
GB201820452D0 (en) Compounds and their use for the treatment of alpha1-antitryspin deficiency
GB201820455D0 (en) Compounds and their use for the treatment of alpha1-antitryspin deficiency
GB201820451D0 (en) Compounds and their use for the treatment of alpha1-antitryspin deficiency
HK40020424A (en) Sulfinylpyridines and their use in the treatment of cancer
HK40021223A (en) Bicyclic compounds and their use in the treatment of cancer